Biosimilar preparations in oncology – also manufacturers of original drug associations in AIFP are developing biosimilars

01/2018

Mgr. Jakub Dvořáček, MHA

Asociace inovativního farmaceutického průmyslu, Praha

SUMMARY

Biosimilar medicinal products are not new, but monoclonal antibodies have raised the interest of the general public. At present, about 30 biosimilar products are available or are expected to be marketed prior to the very careful regulatory procedure. Oncology is one of the most economically demanding disciplines, and new biological drugs represent an extreme increase in health care costs. Increased availability of care is expected from biosimilar drugs such as rituximab, trastuzumab, bevacizumab and others.

KEY WORDS

biosimilar medicinal products, biological treatment, oncology, monoclonal antibodies